Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ASND 
Ascendis Pharma AS (ASND)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/03/2025: ASND (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -14.15% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.10B USD | Price to earnings Ratio - | 1Y Target Price 209.53 |
Price to earnings Ratio - | 1Y Target Price 209.53 | ||
Volume (30-day avg) 391986 | Beta 0.61 | 52 Weeks Range 111.09 - 169.37 | Updated Date 04/2/2025 |
52 Weeks Range 111.09 - 169.37 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -103.97% | Operating Margin (TTM) 0.22% |
Management Effectiveness
Return on Assets (TTM) -17.38% | Return on Equity (TTM) -818.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9426210879 | Price to Sales(TTM) 25.04 |
Enterprise Value 9426210879 | Price to Sales(TTM) 25.04 | ||
Enterprise Value to Revenue 23.95 | Enterprise Value to EBITDA -20.75 | Shares Outstanding 60124700 | Shares Floating 59372631 |
Shares Outstanding 60124700 | Shares Floating 59372631 | ||
Percent Insiders 0.78 | Percent Institutions 110.47 |
Analyst Ratings
Rating 4.73 | Target Price 189.53 | Buy 2 | Strong Buy 12 |
Buy 2 | Strong Buy 12 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ascendis Pharma AS
Company Overview
History and Background
Ascendis Pharma AS was founded in 2006 in Denmark and focuses on developing therapies for unmet medical needs. The company has evolved through strategic partnerships and a focus on innovative endocrinology solutions.
Core Business Areas
- Endocrinology: Focuses on therapies for growth disorders, particularly utilizing TransCon technology for sustained release of drugs.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical industry. The organizational structure is designed to support research, development, and commercialization of endocrinology therapies.
Top Products and Market Share
Key Offerings
- Skytrofa (lonapegsomatropin-tcgd): A long-acting growth hormone for pediatric growth hormone deficiency (GHD). Competitors include Pfizer's Genotropin and Novo Nordisk's Norditropin. Skytrofa had US sales of $227.3 million in 2023.
Market Dynamics
Industry Overview
The endocrinology market is growing, driven by increasing prevalence of growth disorders and advancements in therapeutic options.
Positioning
Ascendis Pharma AS is positioning itself as a leader in endocrinology, particularly with its TransCon technology and long-acting hormone therapies.
Total Addressable Market (TAM)
The global growth hormone deficiency market is expected to reach billions of dollars. Ascendis Pharma AS aims to capture a significant portion of this market with Skytrofa and future products.
Upturn SWOT Analysis
Strengths
- Innovative TransCon technology
- Strong intellectual property portfolio
- Successful launch of Skytrofa
- Experienced management team
Weaknesses
- Reliance on a single primary product (Skytrofa)
- High R&D expenses
- Limited commercial infrastructure compared to larger competitors
- Dependence on regulatory approvals
Opportunities
- Expansion into new indications for TransCon technology
- Geographic expansion
- Strategic partnerships
- Development of next-generation endocrinology therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Pricing pressures
Competitors and Market Share
Key Competitors
- PFE
- NVO
Competitive Landscape
Ascendis Pharma AS competes with established pharmaceutical companies in the endocrinology market. Its TransCon technology offers a competitive advantage, but it faces challenges in terms of scale and resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Ascendis Pharma AS has experienced rapid revenue growth following the approval and launch of Skytrofa.
Future Projections: Analysts project continued revenue growth driven by Skytrofa sales and potential new product approvals.
Recent Initiatives: Expansion of the Skytrofa label to younger patients and geographic expansion of its availability are key initiatives.
Summary
Ascendis Pharma AS is a growing pharmaceutical company with an innovative technology platform. It has experienced significant revenue growth but is still operating at a net loss due to high R&D spending. The company needs to successfully expand the market for Skytrofa and its pipeline. Regulatory hurdles and increasing competition represent threats to its long-term success.
Similar Companies
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
NVO
Novo Nordisk A/S
NVO
Novo Nordisk A/S
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Ascendis Pharma AS Financial Reports
- Analyst Reports
- Company Presentations
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change and may not be entirely accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ascendis Pharma AS
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-01-28 | President, CEO, Member of Executive Board & Executive Director Mr. Jan Moller Mikkelsen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1017 | Website https://ascendispharma.com |
Full time employees 1017 | Website https://ascendispharma.com | ||
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.